Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study

Exclusion Criteria

• •Positive acute vascular response test for idiopathic/hereditary/drug-related arterial pulmonary hypertension
• •Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) with arterial pulmonary
• •Pregnant or lactating women
• •Suffering from mental illness or cognitive impairment
• •PAH patients with concurrent malignant tumors
• •Patients with moderate to severe hepatic impairment, renal impairment, and severe anemia
• •Currently participating in other interventional clinical studies
• •Key clinical data is incomplete, or the investigator considers that the patient has other factors that make them unsuitable for this study.